TRIUMPH-2: Obesity in adults with established type 2 diabetes
Both act as excellent companion technologies for GLP-1 users as they transition to eating different foods and products from CPG brands than they have historically, while still providing the choice and flexibility that users want
And, depending on your health and family history they may not be appropriate for you
Neuroscience 82 , 12131223 (1998)
Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited, Boehringer Ingelheim International GmbH, Amgen Inc., AstraZeneca PLC, Roche Holding AG, Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Structure Therapeutics Inc., Altimmune, Inc., United Laboratories International Holdings Limited, Entera Bio Ltd., OPKO Health, Inc., Viking Therapeutics, Inc., Twist Bioscience Corporation and others GLP-1 agonists market is segmented based on Product, Indication , Route of Administration, Distribution Channel and Region
Neither has gone through Phase 3 clinical trials for musculoskeletal indications